Epstein-Barr virus-associated T-cell lymphoma: A case of eyelid swelling and intramuscular infiltration mimicking dermatomyositis

British Journal of Dermatology

Volumn 147, Issue 6, 2002, Pages 1244-1248

  Shirasaki, Fumiaki ^a   Taniuchi, K ^a   Matsushita, T ^a   Hamaguhi, Y ^a   Takata, M ^a   Takehara, K ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Chronic active Epstein Barr virus infection; Epstein Barr virus; T cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CREATINE KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CAPILLARY LEAK SYNDROME; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; ERYTHEMA; EYELID EDEMA; FACE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LUNG EDEMA; MULTIPLE ORGAN FAILURE; MUSCLE; NECROSIS; PAPULE; PRIORITY JOURNAL; SKIN; T CELL LYMPHOMA; TREATMENT OUTCOME; VIRUS INFECTION; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; EDEMA; EYELID DISEASE; MIDDLE AGED; SKIN TUMOR; VIROLOGY;

DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; EDEMA; EPSTEIN-BARR VIRUS INFECTIONS; EYELID DISEASES; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; SKIN NEOPLASMS;

EID: 0036886716     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.05037.x     Document Type: Article

References (14)

1. Iwatsuki K, Ohtsuka M, Harada H et al. Clinicopathologic manifestations of Epstein-Barr virus-associated cutaneous lymphoproliferative disorders. Arch Dermatol 1997; 133: 1081-6.
2. Ohtsuka M, Iwatsuki K, Kaneko R et al. Epstein-Barr virus-associated lymphoid hyperplasia of the eyelid characterized by intramuscular infiltration. Br J Dermatol 1999; 140: 358-9.
3. Sato-Matsumura KC, Matsumura T, Kobayashi H et al. Marked swollen erythema of the face together with sicca syndrome as a sign for chronic active Epstein-Barr virus infection. Br J Dermatol 2000; 143: 1351-3.
4. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
5. Iwatsuki K, Xu Z, Ohtsuka M, Kaneko F. Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview. J Dermatol Sci 2000; 22: 181-95.
6. Richinson AB. Chromc, symptomatic Epstein-Barr virus infections. Immunol Today 1986; 7: 13-14.
7. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-6.
8. Ohga S, Nomura A, Takada H. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 2001; 183: 1-7.
9. Lay JD, Tsao CJ, Chen JY et al. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100: 1969-79.
10. Ohshima K, Suzumiya J, Sugihara M et al. CD95 (Fas) ligand expression of Epstein-Barr virus (EBV)-infected lymphocytes: a possible mechanism of immune evasion in chronic active EBV infection. Pathol Int 1999; 49: 9-13.
11. Ishii E, Ohga S, Aoki T et al. Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interleukin-1 and tumor necrosis factor. Acta Haematol 1991; 85: 93-9.
12. Kuzushima K, Yamamoto M, Kimura H et al. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 1996; 103: 192-8.
13. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-9.
14. Gutierrez MI, Judde JG, Magrath IT, Bhatia KG. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res 1996; 56: 969-72.